Status:
RECRUITING
Erectile Dysfunction in Good Prognosis Prostate Cancer : Comparison Between Brachytherapy and Stereotactic Body Radiotherapy
Lead Sponsor:
Center Eugene Marquis
Conditions:
Prostate Cancer
Eligibility:
MALE
18+ years
Phase:
NA
Brief Summary
The TEMPOS-GEniToUrinary Group (GETUG) study is a multicenter, medico-economic study comparing brachytherapy to SBRT in low and intermediate risk prostate cancer, particularly focused on the issue of ...
Eligibility Criteria
Inclusion
- Main inclusion criteria
- Biopsy proven prostate adenocarcinoma,
- Low risk prostate cancer according to d'Amico (T1-T2a and PSA \<10 ng/ml, and Gleason score 6) or intermediate risk prostate cancer according d'Amico but excluding tumor with Gleason score 7 (4 + 3),
- Indication of a curative treatment by brachytherapy validated in multidisciplinary consultation meeting,
Exclusion
- Androgen deprivation therapy,
- Contraindication for prostate Iodine 125 brachytherapy (Prostate volume \> 50 cc, impossibility if general anesthesia).
- Contraindication for Resonance Magnetic Imagery (RMI) (claustrophobia, pacemaker)
- Participation to another research which could have an impact on the study treatment and the outcomes
Key Trial Info
Start Date :
October 4 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 4 2031
Estimated Enrollment :
240 Patients enrolled
Trial Details
Trial ID
NCT03830788
Start Date
October 4 2019
End Date
April 4 2031
Last Update
August 1 2025
Active Locations (20)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinique Claude Bernard
Albi, France
2
ICO Paul Papin
Angers, France, 49055
3
Institut Bergonié
Bordeaux, France
4
Polyclinique Bordeaux-Aquitaine
Bordeaux, France